ArticleCureus2026
A Study of the Significance of Platelet Indices in Patients With Preeclampsia Attending a Tertiary Care Center in Jharkhand.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Preeclampsia is a multisystem hypertensive disorder of pregnancy that remains a major cause of maternal and perinatal morbidity and mortality worldwide. It arises after 20 weeks of gestation and is characterized by new-onset hypertension with proteinuria or end-organ dysfunction. Abnormal placentation and placental ischemia trigger the release of anti-angiogenic factors such as soluble FMS-like tyrosine kinase-1 (sFLT-1) and soluble endoglin, leading to endothelial dysfunction and platelet activation. Consequently, platelet indices, namely, platelet count (PC), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT), may serve as accessible markers of disease severity. Methodology This 18-month observational cross-sectional study was conducted at the Department of Pathology, Rajendra Institute of Medical Sciences (RIMS). Eighty pregnant women (≥18 years, >20 weeks of gestation) with preeclampsia were included. Patients with pre-existing hypertension, chronic renal disease, diabetes mellitus, or hematological disorders were excluded, as these conditions can independently influence platelet count and platelet activation. Their exclusion ensured that changes in platelet indices could be more reliably attributed to preeclampsia rather than confounding comorbidities. Results Among 80 patients (mean age: 26.2 years), most were primigravida and presented near term; 58.75% progressed to eclampsia. Thrombocytopenia was observed in 23.75%, while elevated MPV and PDW were noted in 27.5% and 60%, respectively. PDW showed the strongest correlation with disease severity. Neonatal outcomes were favorable in 96.25% of cases. Conclusions PDW was the platelet index most strongly associated with progression to eclampsia. Platelet count showed a weaker predictive relationship, while MPV and PCT demonstrated a moderate association with increasing disease severity. Overall, platelet indices, particularly PDW, showed a statistically significant association with disease severity, supporting their potential utility in the clinical assessment and monitoring of preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.